Other Government Links Searched via RegsKnowledge:

Example Content from MEDITEXT for 151126-32-8:

Please note: this is an extract of information from a larger document. Full document and details are available by subscription.

ACUTE EXPOSURE INFORMATION

WITH THERAPEUTIC USE

The most frequently reported adverse effects, following therapeutic administration of pramlintide, include nausea, vomiting, anorexia, and headache.

Concomitant administration of pramlintide with one or more antidiabetic agents (eg, insulin, sulfonylureas) increases the risk of hypoglycemia. Severe hypoglycemia associated with pramlintide will generally occur within 3 hours after pramlintide administration.

WITH POISONING/EXPOSURE

Pramlintide overdose information is limited. Severe nausea, vomiting, diarrhea, vasodilatation, and dizziness were reported in healthy volunteers following administration of single 10-mg doses.

Hypoglycemia is not expected after administration of pramlintide alone, but may develop if pramlintide is administered with insulin or other hypoglycemic agents.